A related editorial discusses the findings of this meta-analysis. It highlights the important finding within the study that the proportional reduction in cardiovascular outcomes from blood pressure lowering did not differ by baseline disease history. This suggests that a larger benefit of blood pressure lowering is expected in patients at high or very high absolute risk of cardiovascular events than in those at a lower risk. This analysis included the results of the recent SPRINT trial which included a substantial number of patients with low systolic blood pressure at baseline.